Shukra Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
Shukra Pharmaceuticals has been growing earnings at an average annual rate of 84.3%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 56.1% per year. Shukra Pharmaceuticals's return on equity is 32.2%, and it has net margins of 24%.
Key information
84.3%
Earnings growth rate
59.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 56.1% |
| Return on equity | 32.2% |
| Net Margin | 24.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shukra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 774 | 185 | 56 | 0 |
| 31 Dec 23 | 1,117 | 185 | 58 | 0 |
| 30 Sep 23 | 948 | 91 | 56 | 0 |
| 30 Jun 23 | 743 | 45 | 49 | 0 |
| 31 Mar 23 | 595 | 44 | 54 | 0 |
| 31 Dec 22 | 218 | 11 | 59 | 0 |
| 30 Sep 22 | 248 | 11 | 59 | 0 |
| 30 Jun 22 | 239 | 10 | 52 | 0 |
| 31 Mar 22 | 205 | 8 | 55 | 0 |
| 31 Dec 21 | 131 | 0 | 54 | 0 |
| 30 Sep 21 | 144 | 1 | 52 | 0 |
| 30 Jun 21 | 130 | 1 | 45 | 0 |
| 31 Mar 21 | 112 | 2 | 45 | 0 |
| 31 Dec 20 | 110 | -1 | 43 | 0 |
| 30 Sep 20 | 121 | 1 | 42 | 0 |
| 30 Jun 20 | 119 | 1 | 43 | 0 |
| 31 Mar 20 | 118 | 0 | 49 | 0 |
| 31 Dec 19 | 104 | 8 | 37 | 0 |
| 30 Sep 19 | 63 | 4 | 27 | 0 |
| 30 Jun 19 | 57 | 4 | 22 | 0 |
| 31 Mar 19 | 57 | 5 | 22 | 0 |
| 31 Dec 18 | 40 | -5 | 21 | 0 |
| 30 Sep 18 | 62 | 5 | 19 | 0 |
| 30 Jun 18 | 54 | 10 | 15 | 0 |
| 31 Mar 18 | 53 | 5 | 16 | 0 |
| 31 Dec 17 | 63 | 12 | 13 | 0 |
| 30 Sep 17 | 44 | 3 | 13 | 0 |
| 30 Jun 17 | 52 | 7 | 12 | 0 |
| 31 Mar 17 | 51 | 5 | 12 | 0 |
| 31 Dec 16 | 54 | 3 | 11 | 0 |
| 30 Sep 16 | 45 | 1 | 11 | 0 |
| 30 Jun 16 | 50 | 2 | 11 | 0 |
| 31 Mar 16 | 48 | 1 | 12 | 0 |
| 31 Dec 15 | 19 | 3 | 16 | 0 |
| 30 Sep 15 | 19 | 6 | 16 | 0 |
| 30 Jun 15 | 22 | 2 | 11 | 0 |
| 31 Mar 15 | 26 | 1 | 12 | 0 |
| 31 Dec 14 | 40 | 7 | 11 | 0 |
| 30 Sep 14 | 48 | 2 | 10 | 0 |
| 30 Jun 14 | 46 | -2 | 9 | 0 |
| 31 Mar 14 | 44 | -8 | 12 | 0 |
| 31 Dec 13 | 45 | -39 | 11 | 0 |
| 30 Sep 13 | 44 | -35 | 11 | 0 |
| 30 Jun 13 | 56 | -29 | 11 | 0 |
Quality Earnings: 524632 has a high level of non-cash earnings.
Growing Profit Margin: 524632's current net profit margins (24%) are higher than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524632's earnings have grown significantly by 84.3% per year over the past 5 years.
Accelerating Growth: 524632's earnings growth over the past year (320.7%) exceeds its 5-year average (84.3% per year).
Earnings vs Industry: 524632 earnings growth over the past year (320.7%) exceeded the Pharmaceuticals industry 18.4%.
Return on Equity
High ROE: 524632's Return on Equity (32.2%) is considered high.